Sign in

Matthew Summerville

Managing Director and Senior Research Analyst at D.A. Davidson

Matt Summerville is a Managing Director and Senior Research Analyst at D.A. Davidson, specializing in Industrials, Technology, and related sectors with significant expertise in both Industrial Technology and Financial Technology research. He currently covers 18 to 35 companies primarily on the NYSE and NASDAQ, including notable names like Symbotic, Modine Manufacturing, and others, and holds a 62% success rate with an average annualized return of approximately 29.5% on his stock recommendations. Summerville joined D.A. Davidson in January 2018 after nearly 20 years as a sell-side analyst at Alembic Global Advisors and KeyBanc Capital Markets, and holds a bachelor's degree in finance magna cum laude from the University of Toledo. He is regulated by FINRA (CRD#: 3076163), registered with D.A. Davidson & Co., and is recognized by several industry platforms for his exceptional performance and coverage depth.

Matthew Summerville's questions to AMETEK INC/ (AME) leadership

Question · Q3 2025

Matthew Summerville of D.A. Davidson asked for more details on Paragon Medical's organic sales and order growth, its future organic algorithm, and current profitability relative to initial acquisition expectations, also seeking clarification on the improved outlook for the process market.

Answer

Chairman and CEO David Zapico stated Paragon Medical had outstanding double-digit orders growth, is halfway through a restructuring to reduce costs, and is winning new programs. Margins are now in line with AMETEK's overall margins, with expectations to reach 35%+ EBITDA. For the process market, Zapico noted sequential improvement across all markets and geographies except China, with increasing visibility and a strong pipeline, anticipating an excellent 2026 for the segment.

Ask follow-up questions

Question · Q3 2025

Matthew Summerville asked for more details on Paragon Medical's organic sales, order growth, future organic algorithm, and profitability trends, and later inquired about the basis for optimism in the process market.

Answer

David Zapico, Chairman and CEO, highlighted Paragon's outstanding double-digit order growth, ongoing restructuring, new program wins, and current margins aligning with AMETEK's, with potential for 35%+ EBITDA. For the process market, Mr. Zapico noted sequential improvement across all geographies except China, with improving visibility and anticipation of an excellent 2026.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts